AFFILIATIONS
1 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
2 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
3 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
4 Henan Cancer Hospital, Zhengzhou, China
5 Sun Yat-sen University Cancer Center, Guangzhou, China
6 Beijing Shijitan Hospital, Beijing, China
7 Peking University Third Hospital, Beijing, China
8 Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
9 Liaoning Cancer Hospital & Institute, Shenyang, China
10 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
11 Xinqiao Hospital, Army Medical University, Chongqing, China
12 Yantaishan Hospital, Yantai, China
13 First Hospital of China Medical University, Shenyang, China
14 First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
15 Chen zhou First People's Hospital, Chenzhou, China
16 Chen zhou First People's Hospital, Chenzhou, China
17 Shanxi Provincial Cancer Hospital, Taiyuan, China
18 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
19 Fujian Cancer Hospital, Fuzhou, China
20 Hunan Cancer Hospital, Changsha, China
21 The First Hospital of Hebei Medical University, Shijiazhuang, China
22 Shengjing Hospital of China Medical University, Shenyang, China
23 The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
24 The First Affiliated Hospital of Ningbo University, Ningbo, China
25 First Hospital of Longyan City, Longyan, China
26 West China Hospital of Sichuan University, Chengdu, China
27 The first affiliated hospital, Hainan Medical University, Haikou, China
28 Third Xiangya Hospital of Central South University, Changsha, China
29 Third Xiangya Hospital of Central South University, Changsha, China
30 Affiliated Hospital of Binzhou Medical College, Binzhou, China
31 The 940th Hospital of the Joint Support Force of the People's Liberation Army, Lanzhou, China
32 Xijing Hospital, Xi'An, China
33 Xijing Hospital, Xi'An, China
34 China Southern Medical University Integrated Traditional Chinese and Western Medicine Hospital, Guangzhou, China
35 Affiliated Hospital of Guizhou Medical University, Guiyang, China
36 The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
37 The Second Hospital of Dalian Medical University, Dalian, China
38 Cancer Hospital of Shandong First Medical University, Jinan, China
39 Cancer Hospital of Shandong First Medical University, Jinan, China
40 Evopoint Biosciences Co., Ltd., Chengdu, China
41 Evopoint Biosciences Co., Ltd., Shanghai, China
42 Evopoint Biosciences Co., Ltd., Suzhou, China
43 Evopoint Biosciences Co., Ltd., Shanghai, China
44 Evopoint Biosciences Co., Ltd., Suzhou, China
45 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
ABSTRACT
Background: Patients (Pts) with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) and follicular lymphoma (FL) have limited treatment options and poor outcomes. Enhancer of zeste homolog 2 (EZH2), a methyltransferase involved in epigenetic regulation, is frequently overexpressed in PTCL and harbors gain-of-function mutations in a subset of FL, both of which are associated with disease progression. Igermetostat maleate (igermetostat) is a novel, potent, highly selective small molecule inhibitor of EZH2. Here, we report the updated efficacy, pharmacokinetic (PK), pharmacodynamics (PD), and safety data from a phase 1/2 study of igermetostat in pts with R/R PTCL and FL.
Methods: This study was a first-in-human, multicenter, open-label, phase 1/2 trial conducted at 50 sites in China. Adult pts aged ≥ 18 years with ≥ 2 lines of systemic therapies were eligible to be enrolled. Dose-escalation was performed using a standard 3+3 design across 6 dose levels of igermetostat (accelarated titration at the first dose), ranging from 100 mg to 2000 mg, administered orally twice daily (BID). Dose-expansion was subsequently conducted at 800 mg and 1200 mg BID in pts with R/R PTCL and FL. The trial was registered on ClinicalTrials.gov (NCT06558513).
Results: As of March 26, 2026, a total of 120 pts had been enrolled, including 19 in the dose-escalation phase and 101 in the dose-expansion phase. The median follow-up time was 10.14 months (mos). The median number of prior lines of systemic therapy was 3. Among the efficacy-evaluable PTCL subgroup (n=37) at 1200mg BID, 94.6% had received prior histone deacetylase (HDAC) inhibitor therapy. The objective response rate (ORR) was 73.0% (95% confidence interval [CI]: 55.88%-86.21%), including 12 (32.4%) complete responses (CRs) and 15 (40.5%) partial responses (PRs). The median time to response (mTTR), median duration of response (mDOR), median progression-free survival (mPFS), and median overall survival (mOS) were 1.87 mos, 13.9 mos, 12.9 mos, and 41.9 mos, respectively. The ORR was 75.0% in both PTCL not otherwise specified (PTCL-NOS; n=16) and angioimmunoblastic T-cell lymphoma (AITL; n=20), the two major subtypes of PTCL. Among the efficacy-evaluable FL subgroup at 1200mg BID (n=30), 93.3% had received prior anti-CD20 antibody therapy. The ORR of all FL, EZH2 wild type FL, and EZH2 mutant FL was 76.7% (23/30), 68.4% (13/19), and 90.0% (9/10), respectively. Igermetostat steady-state exposure (AUCss,0-τ) increased in an approximately dose-proportional manner from 100 to 1600 mg after multiple dosing. Methylation of H3K27 was significantly inhibited (C1D28 inhibition rate: 78%) after multiple dosing of 1200 mg BID. Among the 120 enrolled pts, serious adverse events (SAEs) occurred in 48 pts (40%), and the incidence of treatment-related SAEs assessed by the investigator was 25%. Grade ≥ 3 treatment-related adverse events (TRAEs) in ≥10% of pts included anemia (17.5%), neutrophil count decreased (17.5%), white blood cell count decreased (15.0%), platelet count decreased (13.3%), and lymphocyte count decreased (13.3%). The safety profile was generally consistent with previous findings, and no new safety signal was identified.
Conclusions: Igermetostat 1200 mg BID demonstrated robust and durable anti-tumor efficacy along with a favorable safety and PK/PD profile in heavily pretreated pts with R/R PTCL and FL. These findings support continued clinical development of igermetostat in these indications.